The blood-brain barrier (BBB) maintains homeostasis by blocking toxic molecules from the circulation, but drugs are blocked at the same time. When the dose is increased to enhance the drug concentration in the central nervous system, there are side-effects on peripheral organs. In recent years, genetic therapeutic agents and small molecules have been used in various strategies to penetrate the BBB while minimizing the damage to systemic organs. In this review, we describe several representative methods to circumvent or cross the BBB, including chemical and physical strategies.
Introduction
Treatment of central nervous system (CNS) diseases is challenged by the difficulty in drug delivery through the blood-brain barrier (BBB). Although drug mechanism research has become quite sophisticated in recent years, the vast majority of drugs are blocked by the BBB and thus fail to reach the brain, making it diffi cult to treat intracranial disease [1] .
The BBB has the function of selective permeability w h i c h p r e v e n t s b a c t e r i a a n d o t h e r p a t h o g e n i c microorganisms from entering the brain while at the same time allowing oxygen and other vital compounds to traverse from the blood to the brain. However, it also fends off drugs, and so is an obstacle to treating brain diseases.
Methods for drug delivery to the brain can be divided into two types: invasive and non-invasive. The invasive methods can achieve a high local drug concentrations by direct injection or intracerebroventricular delivery but also has side-effects such as infection or trauma. Besides, the drug concentration decreases exponentially as a function of distance from the injection site. It is also hard to deliver drugs repeatedly and patients hesitate to accept invasive treatments. For these reasons, we focus on the noninvasive drug-delivery strategies.
Structure of BBB
The BBB is a layer of endothelial cells on the basement membrane lining almost 99% of the brain capillary surface, continuously coupled with perivascular cells [2] , such as pericytes, smooth muscle cells, astrocytes, and microglia ( Fig. 1 ) [3] . Normally the BBB excludes ionic water-soluble drugs with a diameter >180 nm [4] .
Transplantation studies have shown that the properties of the endothelial cells that constitute the BBB are not innate [5] , but are induced in the special microenvironment of the CNS [6] . The BBB is formed during embryogenesis when endothelial cells enter the CNS. One week before astrocyte formation, pericytes are recruited to the neonatal vessels and regulate the functions of the BBB, including the generation of tight junctions (TJs) and vesicle traffi cking in brain microvascular endothelial cells (BMECs) [7] [8] [9] , a major component of the BBB [10] . Pericytes are a prerequisite 258 for the formation of the BBB and determine part of its permeability by inhibiting the expression of molecules that increase BBB permeability and immune cell infiltration.
However, they do not induce BBB-specifi c gene expression in CNS endothelial cells [11, 12] . Astrocytes induce BBB formation after birth because of the close spatial relation between astrocytes and BMECs. The timing of BBB formation has been controversial. Laboratory mice with null and hypomorphic Pdgfrb alleles that have defects in pericyte generation illustrated that the interactions between pericytes and BMECs are critical in regulating BBB permeability. This effect is caused by the inhibition of specifi c proteins that can increase the permeability of the BBB [13] [14] [15] .
The permeability of the BBB in drug delivery remains a problem, although many drugs have been developed in an attempt to combat it. Several available strategies for the safe and effective delivery of drugs are described below.
A Drug-Delivery Approach to Bypassing the BBB
Intranasal delivery of drugs is a potential strategy to bypass the BBB [16] . The effectiveness of intranasal delivery is determined by administration factors and physicochemical properties, such as the patient's head position, dosing device, drug volume, pH value, osmotic pressure, and drug solubility. Intranasal delivery has been highly regarded because it is noninvasive, safe, and simple. Since its early use by W illiam Ewart [17] for the treatment of diphtheria, intranasal delivery has been confi rmed as a promising route of administration. On the other hand, its use is relatively limited. However, the method has been modifi ed by various additions such as penetration enhancers, adhesion agents, and nanoparticles, which can significantly increase the efficiency of drug delivery. Wu et al. [18] have successfully delivered stem cells using the intranasal approach as a therapy for experimental allergic encephalomyelitis in rats, an animal model of multiple sclerosis. Nasal glucagonlike peptide-1 [19] has already been used in patients. This is a promising development for patients with diabetes, and has the potential that insulin may be administered in a similar way. Future research is needed to further reveal the mechanisms of nasal drug delivery and at the same time improve the technology and solution preparation. This will achieve a better targeting, improved effectiveness, and higher drug concentrations.
New Drug-Delivery Approaches to Crossing the

BBB
Relevant Carriers in Cerebral Microvascular
Endothelia
Receptors on the surface membranes of cells can help drug delivery. Common carriers include medium-chain fattyacid carriers, neutral amino-acid carriers, a monocarboxylic carrier, cation transporters, and the adenosine purine carrier.
Exosomes [20] Scientists at the University of Oxford have used protein carriers called exosomes to transport drug molecules to the brain cells of laboratory mice. Exosomes are membrane vesicles released by a variety of cells such as dendritic cells [21, 22] . They transport material back and forth through the BBB. Exosomes are fi rst extracted from mice. Then, a CNS-specific rabies viral glycoprotein is attached to the acetylcholine receptor, and fused to the exosomes. Finally, an siRNA is placed in the exosomes and the complex is intravenously injected into mice.
Experiments have confirmed that the siRNA is delivered to the brain and binds to its receptors on brain cells.
This results in a 60% decline of β-secretase 1 (BACE1) expression, a gene associated with Alzheimer's disease [23] . Transferrin receptor [25] The transferrin receptor (TfR) is a key cell-surface molecule that regulates the uptake of ironbound transferrin [26] . Plasma soluble TfR concentrations refl ect the receptor density on cells and the number of cells expressing the receptor. Therefore, it is closely related to cellular iron demand and the erythroid proliferation rate. TfR is frequently overexpressed in cancer cells [27] .
Recently, transferrin-targeted conjugates have shown promise in reversing drug resistance in cancer cells, and transferrin immunotoxins with a diphtheria toxin mutant covalently bound to transferrin have shown promise for the treatment of glioblastoma in clinical trials [28] . 
Nanoparticles [29]
Nanoparticles make up solid colloids composed of polymers or lipid particles of 10-1000 nm (usually 50-300 nm). A drug can be embedded within a particle's substrate or attached to its surface [30] . Drugs are transported in a controlled time period to a targeted location in vivo.
During this process, certain principles should be followed:
nanoparticles used as drug carriers should be non-toxic, biodegradable, and biocompatible; have a diameter <100 nm and no aggregation reaction in blood, as well as an effi cient production process [31] .
Poly-nanoparticles such as PBCA-NPs [32] [33] [34] [35] (butylcyanoacrylate), PEG [36] [37] [38] [39] [40] (polyethylene glycol), liposomes [41] [42] [43] , P-gp (P-glycoprotein), and even superparamagnetic iron oxide nanoparticles [37] have been used for drug delivery.
To investigate the mechanisms behind nanoparticles, it must be recognized that materials on the nanoscale take on new biological and physical characteristics. For example, there may be a ubiquitous toxic effect on BMECs.
A surfactant effect due to the solubilization of lipids in the endothelial cell membrane may lead to membrane fl uidization and therefore enhanced drug permeability of the BBB.
Opening TJs between BMECs can allow drugs to pass through the BBB alone or with nanoparticles. Another option is receptor-mediated endocytosis followed by transcytosis into the CNS or drug release in endothelial cells [31] . [44] between Endothelial
Adjustment of Tight Junctions
Cells of the BBB
There are three means of barrier disruption (Table 1): osmotic, pharmacological, and mechanical (focused ultrasound (FUS) with microbubbles).
Many drugs are slow to exert an effect, as has been shown in in vitro studies [51] . This is due to the low drug sonication most of the time [52] . Drug delivery by this method has been verifi ed by extensive research [53] [54] [55] [56] [57] .
The mechanisms by which ultrasound opens the BBB rely on various physical characteristics and are closely associated with biological processes. Electron microscopy has confi rmed that ultrasound causes enlarged biomembrane lacunae with no evident tissue damage both in vivo and in vitro. It has also been confirmed that after ultrasound irradiation, the capillary permeability increases, including endocytosis, opening of TJs, and free transportation through the endothelial lacunae [58] .
FUS is often used in oncotherapy, but it has not reached the same level of maturity in the field of BBB- and epithelial cells resulting in a targeted zone of oxygen deficiency [59] . Research is focused on adjusting the parameters of FUS to make it effective in drug delivery [60] .
Tunneling Nanotubes
The tunneling nanotube (TNT) [61] [62] [63] [64] [65] is a new general communication method between mammal cells. TNTs are somewhat similar to the protoplasmic connections in plants, but they differ in structure and function. TNTs have already been used to transport particles outside or inside the BBB [66] . In particular, mitochondria are the most common particles transported from one cell to another through TNT (Fig. 2 ) [67] [68] [69] [70] [71] .
Interestingly, researchers at UCLA's Jonsson
Comprehensive Cancer Center found that RNA can be transported into mitochondria, but little is known about the mechanism. They found that polynucleotide phosphorylase (PNPASE) protein [72, 73] plays an important role in transporting RNA into mitochondria. When the expression of PNPASE is reduced, the amount of RNA entering mitochondria declines; PNPASE affects the RNAencoding process of the mitochondrial genome and the synthesis of proteins necessary to sustain electron transfer.
When PNPASE expression is reduced, mitochondrial [45] 1980s [46] 1940s for noninvasive ablation in brain [47] Reagent Hypertonic solution of 25% mannitol Bradykinin [48] RMP-7 [49] Nano-microbubbles RNA accumulates, unprocessed protein translation is suppressed, and energy generation is hampered, leading to the arrest or inhibition of cell growth. According to the research, PNPASE mediates the transport of cytoplasmic RNA for energy production by mitochondria. However, no experiment using current detection methods has been able to confi rm this theory. If we could combine TNTs with PNPASE-dependent RNA, import them into mitochondria, and transport mitochondria into BMECs [74] transcending the TJs between them, a direct route to brain would be available.
Conclusion
The BBB impedes the entry of many drugs into the CNS. 
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